The house dust mite allergy market size has grown rapidly in recent years. It will grow from $2.37 billion in 2025 to $2.7 billion in 2026 at a compound annual growth rate (CAGR) of 14.3%. The growth in the historic period can be attributed to rising prevalence of allergic conditions, increased awareness of respiratory allergies, expansion of diagnostic testing availability, growing use of antihistamine medications, improvements in allergy treatment protocols.
The house dust mite allergy market size is expected to see rapid growth in the next few years. It will grow to $4.62 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to increasing adoption of personalized immunotherapy, rising focus on preventive allergy care, expansion of home-based allergy management, growing demand for long-term symptom control, advancements in biologic allergy treatments. Major trends in the forecast period include increasing adoption of immunotherapy-based treatments, rising use of sublingual allergy tablets, growing demand for long-term allergy management solutions, expansion of early diagnostic testing adoption, enhanced focus on personalized allergy treatment.
The increasing incidence of asthma diseases is anticipated to support the growth of the house dust mite allergy market in the coming years. Asthma diseases are chronic inflammatory conditions of the airways marked by recurrent symptoms such as shortness of breath, wheezing, chest tightness, and coughing. The prevalence of asthma is rising largely due to escalating environmental pollution, which aggravates airway inflammation and increases sensitivity to airborne allergens. As asthma cases continue to expand rapidly, demand within the house dust mite allergy market is increasing, prompting companies to adopt solutions that help minimize allergen exposure and improve respiratory health outcomes. For example, in June 2025, according to the American Lung Association, a United States-based nonprofit health organization, asthma prevalence among adults varied significantly across United States jurisdictions in 2023, ranging from 7.1% in Mississippi to 14.1% in Puerto Rico. Therefore, the growing prevalence of asthma diseases is driving demand for house dust mite allergy-related solutions.
Major companies in the house dust mite allergy market are concentrating on developing innovative solutions, such as sublingual tablets aimed at treating house dust mite allergies, to tackle the rising prevalence of these allergies. A sublingual tablet for treating house dust mite allergies is a form of immunotherapy where a tablet is placed under the tongue, allowing it to dissolve and release small doses of the allergen that triggers the allergy. For example, in January 2023, ALK-Abelló A/S, a pharmaceutical company based in Denmark, received FDA approval for ODACTRA, a sublingual tablet designed for adolescents aged 12 to 17, thereby expanding its previous indication for adults. This approval meets a critical need, as nearly 50% of allergy sufferers are sensitive to house dust mites. Clinical trials showed that ODACTRA effectively alleviated allergy symptoms and had a safety profile comparable to that seen in adults. Although the treatment is generally well-tolerated, patients are advised to keep auto-injectable epinephrine available due to the risk of severe allergic reactions.
In September 2025, Stallergenes Greer, a France-based biopharmaceutical company specializing in allergen immunotherapy, entered into a partnership with Nuance Pharma to broaden the commercialization of its house dust mite sublingual immunotherapy tablet, Actair, across China. Through this collaboration, the companies seek to enhance access to evidence-based allergy treatments and reinforce the availability of advanced immunotherapy options for patients suffering from house dust mite-induced allergic rhinitis. Nuance Pharma is a China-based biopharmaceutical company focused on respiratory, immunology, and specialty-care therapeutics.
Major companies operating in the house dust mite allergy market are Allergy Therapeutics Plc, Bayer AG, Catalent Inc., GSK Plc, Merz Pharma GmbH & Co KGaA, Sanofi S A, Shionogi & Co. Ltd., Stallergenes Greer International AG, Merck & Co. Inc., Torii Pharmaceutical Co. Ltd., Ergomed PLC, DMS Group, HAL Allergy Group, Trio Lifescience Private Limited, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Johnson and Johnson Inc., Circassia Pharmaceuticals Plc, Biomay Ag, GlaxoSmithKline.
North America was the largest region in the house dust mite allergy market in 2025. Asia-pacific is expected to be the fastest-growing region in the house dust mite allergy market report during the forecast period. The regions covered in the house dust mite allergy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the house dust mite allergy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the house dust mite allergy market by increasing costs of imported pharmaceutical ingredients, diagnostic kits, immunotherapy formulations, and medical testing equipment. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported allergy treatments, while Asia-Pacific faces pricing pressure on pharmaceutical exports. These tariffs are raising treatment costs and diagnostic expenses. However, they are also encouraging local drug manufacturing, regional diagnostic kit production, and increased investment in domestic allergy treatment solutions.
The house dust mite allergy market research report is one of a series of new reports that provides house dust mite allergy market statistics, including house dust mite allergy industry global market size, regional shares, competitors with a house dust mite allergy market share, detailed house dust mite allergy market segments, market trends and opportunities, and any further data you may need to thrive in the house dust mite allergy industry. This house dust mite allergy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
House dust mite allergy refers to an allergic reaction triggered by small insects commonly found in household dust. This encompasses the treatment methods employed to address allergic responses such as sneezing and other allergy-related conditions.
The primary product types for managing house dust mite allergy include tablets, nasal drops, and injectables. Tablets represent a compact, solid-dose form that may contain medications with or without excipients. Treatment modalities encompass medication, immunotherapy, nasal irrigation, and other approaches. Diagnosis involves methods such as the skin prick test (SPT) and specific immunoglobulin E (IgE) blood test, among others, utilizing various dosage forms such as solid and liquid. These products find application across diverse end-users, including hospitals, homecare settings, specialty clinics, and others.
The house dust mite allergy market consists of sales of prescription drugs and over-the-counter drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The house dust mite allergy market size is expected to see rapid growth in the next few years. It will grow to $4.62 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to increasing adoption of personalized immunotherapy, rising focus on preventive allergy care, expansion of home-based allergy management, growing demand for long-term symptom control, advancements in biologic allergy treatments. Major trends in the forecast period include increasing adoption of immunotherapy-based treatments, rising use of sublingual allergy tablets, growing demand for long-term allergy management solutions, expansion of early diagnostic testing adoption, enhanced focus on personalized allergy treatment.
The increasing incidence of asthma diseases is anticipated to support the growth of the house dust mite allergy market in the coming years. Asthma diseases are chronic inflammatory conditions of the airways marked by recurrent symptoms such as shortness of breath, wheezing, chest tightness, and coughing. The prevalence of asthma is rising largely due to escalating environmental pollution, which aggravates airway inflammation and increases sensitivity to airborne allergens. As asthma cases continue to expand rapidly, demand within the house dust mite allergy market is increasing, prompting companies to adopt solutions that help minimize allergen exposure and improve respiratory health outcomes. For example, in June 2025, according to the American Lung Association, a United States-based nonprofit health organization, asthma prevalence among adults varied significantly across United States jurisdictions in 2023, ranging from 7.1% in Mississippi to 14.1% in Puerto Rico. Therefore, the growing prevalence of asthma diseases is driving demand for house dust mite allergy-related solutions.
Major companies in the house dust mite allergy market are concentrating on developing innovative solutions, such as sublingual tablets aimed at treating house dust mite allergies, to tackle the rising prevalence of these allergies. A sublingual tablet for treating house dust mite allergies is a form of immunotherapy where a tablet is placed under the tongue, allowing it to dissolve and release small doses of the allergen that triggers the allergy. For example, in January 2023, ALK-Abelló A/S, a pharmaceutical company based in Denmark, received FDA approval for ODACTRA, a sublingual tablet designed for adolescents aged 12 to 17, thereby expanding its previous indication for adults. This approval meets a critical need, as nearly 50% of allergy sufferers are sensitive to house dust mites. Clinical trials showed that ODACTRA effectively alleviated allergy symptoms and had a safety profile comparable to that seen in adults. Although the treatment is generally well-tolerated, patients are advised to keep auto-injectable epinephrine available due to the risk of severe allergic reactions.
In September 2025, Stallergenes Greer, a France-based biopharmaceutical company specializing in allergen immunotherapy, entered into a partnership with Nuance Pharma to broaden the commercialization of its house dust mite sublingual immunotherapy tablet, Actair, across China. Through this collaboration, the companies seek to enhance access to evidence-based allergy treatments and reinforce the availability of advanced immunotherapy options for patients suffering from house dust mite-induced allergic rhinitis. Nuance Pharma is a China-based biopharmaceutical company focused on respiratory, immunology, and specialty-care therapeutics.
Major companies operating in the house dust mite allergy market are Allergy Therapeutics Plc, Bayer AG, Catalent Inc., GSK Plc, Merz Pharma GmbH & Co KGaA, Sanofi S A, Shionogi & Co. Ltd., Stallergenes Greer International AG, Merck & Co. Inc., Torii Pharmaceutical Co. Ltd., Ergomed PLC, DMS Group, HAL Allergy Group, Trio Lifescience Private Limited, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Johnson and Johnson Inc., Circassia Pharmaceuticals Plc, Biomay Ag, GlaxoSmithKline.
North America was the largest region in the house dust mite allergy market in 2025. Asia-pacific is expected to be the fastest-growing region in the house dust mite allergy market report during the forecast period. The regions covered in the house dust mite allergy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the house dust mite allergy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the house dust mite allergy market by increasing costs of imported pharmaceutical ingredients, diagnostic kits, immunotherapy formulations, and medical testing equipment. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported allergy treatments, while Asia-Pacific faces pricing pressure on pharmaceutical exports. These tariffs are raising treatment costs and diagnostic expenses. However, they are also encouraging local drug manufacturing, regional diagnostic kit production, and increased investment in domestic allergy treatment solutions.
The house dust mite allergy market research report is one of a series of new reports that provides house dust mite allergy market statistics, including house dust mite allergy industry global market size, regional shares, competitors with a house dust mite allergy market share, detailed house dust mite allergy market segments, market trends and opportunities, and any further data you may need to thrive in the house dust mite allergy industry. This house dust mite allergy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
House dust mite allergy refers to an allergic reaction triggered by small insects commonly found in household dust. This encompasses the treatment methods employed to address allergic responses such as sneezing and other allergy-related conditions.
The primary product types for managing house dust mite allergy include tablets, nasal drops, and injectables. Tablets represent a compact, solid-dose form that may contain medications with or without excipients. Treatment modalities encompass medication, immunotherapy, nasal irrigation, and other approaches. Diagnosis involves methods such as the skin prick test (SPT) and specific immunoglobulin E (IgE) blood test, among others, utilizing various dosage forms such as solid and liquid. These products find application across diverse end-users, including hospitals, homecare settings, specialty clinics, and others.
The house dust mite allergy market consists of sales of prescription drugs and over-the-counter drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. House Dust Mite Allergy Market Characteristics
3. House Dust Mite Allergy Market Supply Chain Analysis
4. Global House Dust Mite Allergy Market Trends and Strategies
5. House Dust Mite Allergy Market Analysis of End Use Industries
7. Global House Dust Mite Allergy Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global House Dust Mite Allergy Total Addressable Market (TAM) Analysis for the Market
9. House Dust Mite Allergy Market Segmentation
10. House Dust Mite Allergy Market Regional and Country Analysis
11. Asia-Pacific House Dust Mite Allergy Market
12. China House Dust Mite Allergy Market
13. India House Dust Mite Allergy Market
14. Japan House Dust Mite Allergy Market
15. Australia House Dust Mite Allergy Market
16. Indonesia House Dust Mite Allergy Market
17. South Korea House Dust Mite Allergy Market
18. Taiwan House Dust Mite Allergy Market
19. South East Asia House Dust Mite Allergy Market
20. Western Europe House Dust Mite Allergy Market
21. UK House Dust Mite Allergy Market
22. Germany House Dust Mite Allergy Market
23. France House Dust Mite Allergy Market
24. Italy House Dust Mite Allergy Market
25. Spain House Dust Mite Allergy Market
26. Eastern Europe House Dust Mite Allergy Market
27. Russia House Dust Mite Allergy Market
28. North America House Dust Mite Allergy Market
29. USA House Dust Mite Allergy Market
30. Canada House Dust Mite Allergy Market
31. South America House Dust Mite Allergy Market
32. Brazil House Dust Mite Allergy Market
33. Middle East House Dust Mite Allergy Market
34. Africa House Dust Mite Allergy Market
36. House Dust Mite Allergy Market Competitive Landscape and Company Profiles
37. House Dust Mite Allergy Market Other Major and Innovative Companies
40. House Dust Mite Allergy Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
House Dust Mite Allergy Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses house dust mite allergy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for house dust mite allergy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The house dust mite allergy market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Tablets; Nasal Drops; Injectable2) By Diagnosis: Skin Prick Test (SPT); Specific Immunoglobulin E (IgE) Blood Test; Other Diagnosis
3) By Dosage Forms: Solid; Liquid
4) By End Users: Hospitals; Homecare; Specialty Clinics; Other End Users
Subsegments:
1) By Tablets: Sublingual Tablets; Oral Tablets2) By Nasal Drops: Antihistamine Nasal Drops; Corticosteroid Nasal Drops
3) By Injectable: Allergen Immunotherapy Injections; Corticosteroid Injections
Companies Mentioned: Allergy Therapeutics Plc; Bayer AG; Catalent Inc.; GSK Plc; Merz Pharma GmbH & Co KGaA; Sanofi S A; Shionogi & Co. Ltd.; Stallergenes Greer International AG; Merck & Co. Inc.; Torii Pharmaceutical Co. Ltd.; Ergomed PLC; DMS Group; HAL Allergy Group; Trio Lifescience Private Limited; Teva Pharmaceutical Industries Ltd.; Eli Lilly and Company; Johnson and Johnson Inc.; Circassia Pharmaceuticals Plc; Biomay Ag; GlaxoSmithKline
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this House Dust Mite Allergy market report include:- Allergy Therapeutics Plc
- Bayer AG
- Catalent Inc.
- GSK Plc
- Merz Pharma GmbH & Co KGaA
- Sanofi S A
- Shionogi & Co. Ltd.
- Stallergenes Greer International AG
- Merck & Co. Inc.
- Torii Pharmaceutical Co. Ltd.
- Ergomed PLC
- DMS Group
- HAL Allergy Group
- Trio Lifescience Private Limited
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- Johnson and Johnson Inc.
- Circassia Pharmaceuticals Plc
- Biomay Ag
- GlaxoSmithKline
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 2.7 Billion |
| Forecasted Market Value ( USD | $ 4.62 Billion |
| Compound Annual Growth Rate | 14.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
